Article citationsMore>>
Rincon, F., Patel, U., Schorr, C., Lee, E., Ross, S., Dellinger, R.P., et al. (2015) Brain Injury as a Risk Factor for Fever upon Admission to the Intensive Care Unit and Association with In-Hospital Case Fatality: A Matched Cohort Study. Journal of Intensive Care Medicine, 30, 107-114. https://doi.org/10.1177/0885066613508266
has been cited by the following article:
-
TITLE:
Bromocriptine in Central Hyperthermia after Severe Traumatic Brain Injury
AUTHORS:
Tamer Zakhary, Ahmed Sabry
KEYWORDS:
Critical, Neurology, Traumatic Brain Injury, Central Hyperthermia, Bromocriptine
JOURNAL NAME:
Open Journal of Emergency Medicine,
Vol.5 No.3,
September
15,
2017
ABSTRACT: Strong evidence showed that fever after traumatic brain injury TBI is associated
with increased mortality. In this study, we tried to evaluate the role of
Bromocriptine in central hyperthermia in patients with severe TBI. This
prospective controlled study was conducted on 50 severe TBI patients who
admitted to the critical care department and confirmed on Computed Tomography
(CT) of the brain and GCS of less than 9 at admission. Then, they were
randomly assigned into 2 groups. Bromocriptine group (25) received bromocriptine
7.5 mg/day during 24 hours from admission through a naso-gastric
(NG) feeding tube. Control group (25) received conventional treatment only.
Temperature was measured every 2 hours. The antipyretic measures used
were the same across all patients enrolled. The primary outcome was number
of patients diagnosed with central hyperthermia. After the discharge of all patients,
there was a statistically significant difference between the 2 groups in
number of patients diagnosed with central hyperthermia (6 (24%) in bromocriptine
group Vs 18 (72%) in control, p = 0.002). There were no differences
in hospital length of stay (p = 0.904) or mortality (p = 0.393). Early administration
of bromocriptine in severe TBI may be associated with lower incidence
of central hyperthermia with no effect on length of stay or mortality.